Differential therapy of heart failure - Which drug for which patient?;Differenzialtherapie der herzinsuffizienz: Welche substanz für welchen patienten?

Internist

Volumn 45, Issue 12, 2004, Pages 1378-1387

  Schillinger, W ^a   Hermann, H P ^a   Hasenfuss G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

ACE inhibitor; Beta blocker; Diabetes mellitus; Heart failure; Renal failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; METOPROLOL; RAMIPRIL; TRANDOLAPRIL;

ASTHMA; COLD; COMORBIDITY; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG PREFERENCE; HEART FAILURE; HUMAN; HYPOTENSION; KIDNEY FAILURE; MEDICAL DECISION MAKING; OBSTRUCTIVE AIRWAY DISEASE; REVIEW; SEX DIFFERENCE; STROKE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DECISION SUPPORT TECHNIQUES; HEART FAILURE, CONGESTIVE; HUMANS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 12344277389     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-004-1290-8     Document Type: Review

References (21)

1. Hoppe UC, Erdmann E (2001) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Deutsche Gesellschaft für Kardiologie. Z Kardiol 90: 218-237
2. Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 22: 1527-1560
3. American College of Cardiology/American Heart Association task force on practice guidelines (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Executive summary. Circulation 104: 2996-3007
4. Komajda M, the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology (2003) The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24: 464-474
5. Taubert G, Bergmeier C, Andresen H (2001) Clinical profile and management of heart failure: rural community hospital vs metropolitan heart center. Eur J Heart Fail 3: 611-617
6. Werner N, Böhm M (2004) ACE-Hemmertherapie bis ans Lebensende? Dtsch Med Wochenschr 129: 1513-1518
7. Shekelle PG, Rich MW, Morton SC et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41: 1529-1538
8. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347: 1403-1411
9. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871-878
10. Wuttke H, Rau T, Heide R et al. (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72: 429-437
11. Carluccio M, Soccio M, De Caterin R (2001) Aspects of gene polymorphism in cardiovascular disease: the renin-angiotensin-system. Eur J Clin Invest 31: 476-488
12. Bristow M (2003) Antiadrenergic therapy of chronic heart failure. Surprises and new opportunities. Circulation 107: 1100-1102
13. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-1009
14. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS (2001) Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation 104: 1985-1991
15. Standl E, Eckert S, Fuchs C et al. (2003) Diabetes mellitus und Herz. In: Scherbaum WA, Landgraf R (Hrsg) Evidenzbasierte Diabetes-Leitlinie DDG. Deutsche Diabetes-Gesellschaft
16. Nesto RW, Bell D, Bonow RO et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941-2948
17. Glaab T, Weiss T (2004) Einsatz von β-Blockern bei kardiovaskulären Erkrankungen und Asthma bronchiale/COPD. Internist. 45: 221-227
18. Salpeter S, Ormiston T, Salpeter E (2004) Cardiovascular Effects of β-agonists in patients with asthma and COPD. A meta-analysis. Chest 125: 2309-2321
19. Chen J, Radford M, Wang Y, Marciniak T, Krumholf H (2001) Effectiveness of β-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 37: 1950-1956
20. Fournier A, Messerli FH, Achard JM, Fernandez L (2004) Cerebroprotection mediated by angiotensin II. A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43: 1343-1347
21. Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (2003) Primäre und sekundäre Prävention der zerebralen Ischämie. In: Diener HC (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart, S 129-144